At a glance
- Originator Servier
- Class Indoles; Neuroprotectants; Nootropics; Thiazolidines
- Mechanism of Action Prolyl endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cognition disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Cognition-disorders in France (PO)
- 05 Aug 2003 A preclinical study has been added to the Alzheimer's disease pharmacodynamics section
- 19 Dec 2000 A clinical study has been added to the pharmacodynamics, pharmacokinetics and adverse events sections